Cargando…

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer

BACKGROUND: Circulating tumor cell (CTC) counts at baseline and follow‐up are an independent prognostic factor in patients receiving standard chemotherapy for non‐small cell lung cancer (NSCLC). This study further explored the role of CTCs in EGFR‐mutated and ALK‐rearranged NSCLC patients administer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tong, Bing, Xu, Yan, Zhao, Jing, Chen, Minjiang, Zhong, Wei, Xing, Jia, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928386/ https://www.ncbi.nlm.nih.gov/pubmed/29582563 http://dx.doi.org/10.1111/1759-7714.12631

Ejemplares similares

Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
por: Tong, Bing, et al.
Publicado: (2017)

Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
por: Lou, Na-Na, et al.
Publicado: (2016)

ALK‐rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report
por: Xu, Yan, et al.
Publicado: (2018)

Case report: Concomitant EGFR mutation and ALK rearrangement in non-small cell lung cancer
por: Hu, Haoyue, et al.
Publicado: (2023)

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer
por: Mori, Mio, et al.
Publicado: (2019)

Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4–ALK-rearranged non–small–cell lung cancer harbored coexisting EGFR mutation
por: Miyanaga, Akihiko, et al.
Publicado: (2013)

Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series
por: Shin, Hong-Joon, et al.
Publicado: (2019)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

The prognostic implications of EGFR mutation and ALK rearrangement for the long‐term outcomes of patients with resected lung adenocarcinomas
por: Kim, Hyungjin, et al.
Publicado: (2019)

Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
por: Dalurzo, Mercedes L, et al.
Publicado: (2021)

Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey
por: Sag, Sebnem Ozemri, et al.
Publicado: (2016)

Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Marino, Federica Zito, et al.
Publicado: (2015)

Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib
por: Ma, Di, et al.
Publicado: (2019)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Oulhen, Marianne, et al.
Publicado: (2021)

EGFR mutations and ROS1 and ALK rearrangements in a large series of non‐small cell lung cancer in South India
por: Tarigopula, Anil, et al.
Publicado: (2020)

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer
por: Xu, Yan, et al.
Publicado: (2020)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
por: Zito Marino, Federica, et al.
Publicado: (2015)

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report
por: Fan, Jun, et al.
Publicado: (2020)

Detecting EGFR mutations and ALK/ROS1 rearrangements in non‐small cell lung cancer using malignant pleural effusion samples
por: Yao, Yi, et al.
Publicado: (2018)

Therapeutic strategies to overcome EGFR mutations as acquired resistance mechanism in ALK-rearranged non-small-cell lung cancer: Case Reports
por: Michaux, Lionel, et al.
Publicado: (2023)

ALK‐rearranged squamous cell carcinoma of the lung
por: Meng, Qiyi, et al.
Publicado: (2021)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
por: Du, Xue, et al.
Publicado: (2018)

Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements
por: Wu, Shafei, et al.
Publicado: (2015)

Small-cell transformation of ALK-rearranged non-small-cell adenocarcinoma of the lung
por: Balla, Agnes, et al.
Publicado: (2018)

A Large-scale Cross-sectional Study of ALK Rearrangements and EGFR Mutations in Non-small-cell Lung Cancer in Chinese Han Population
por: Hong, Shaodong, et al.
Publicado: (2014)

Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
por: Lo Russo, Giuseppe, et al.
Publicado: (2017)

Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer
por: Reyes, Roxana, et al.
Publicado: (2021)

Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
por: Li, Jingjing, et al.
Publicado: (2021)

Sequential EGFR mutation and ALK rearrangement in adenocarcinoma lung, with rare metastasis to bilateral breast, ovary and endometrium
por: Anjali, V.R., et al.
Publicado: (2019)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer
por: Mamdani, Hirva, et al.
Publicado: (2017)

ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
por: Tsakonas, Georgios, et al.
Publicado: (2020)

ALK-rearranged squamous cell carcinoma of the lung
por: Takanashi, Yusuke, et al.
Publicado: (2015)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Differentiating synchronous double primary lung adenocarcinomas from intrapulmonary metastasis by CT features, EGFR mutations and ALK rearrangement status
por: Han, Xiaoyu, et al.
Publicado: (2020)

Circulating tumor cells PD‐L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non‐small‐cell lung cancer
por: Zhou, Qing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2qp7usbimq2neq1vpvr2i0ibru